Kerala government pledges further price cuts for generic SMA drug

Kerala's Health Minister K. Muraleedharan assured the state assembly on Tuesday that the government is committed to bringing down the cost of generic SMA drugs beyond current levels, signalling a phased approach toward providing free medication to all spinal muscular atrophy patients.

The health minister outlined the UDF government's long-term objective of eliminating out-of-pocket expenses for SMA treatment, addressing concerns raised about access to the expensive therapeutic drug used for treating the rare genetic disorder.

The announcement triggered sharp political reactions in the assembly, with the opposition LDF staging a walkout after the speaker rejected an adjournment motion tabled by the coalition. The rejection escalated tensions between the government and opposition benches over healthcare policy implementation.

The debate underscores the growing pressure on state governments across India to make critical medications affordable for patients suffering from rare diseases. SMA treatment costs have been a significant burden on families, making government intervention a key electoral and policy concern in Kerala.

The UDF government's commitment to progressive cost reduction reflects wider efforts to improve healthcare accessibility in the state, though critics have questioned the timeline and feasibility of achieving free treatment for all SMA patients.